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ABSTRACT
Primary myelofibrosis (PMF) is a chronic Philadelphia-negative myeloproliferative 
neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation, 
involving especially the megakaryocyte lineage. To better characterize how the altered 
expression of microRNAs might contribute to PMF pathogenesis, we have previously 
performed the integrative analysis of gene and microRNA expression profiles of PMF 
hematopoietic stem/progenitor cells (HSPCs), which allowed us to identify miR-
494-3p as the upregulated microRNA predicted to target the highest number of 
downregulated mRNAs.
To elucidate the role of miR-494-3p in hematopoietic differentiation, in the 
present study we demonstrated that miR-494-3p enforced expression in normal 
HSPCs promotes megakaryocytopoiesis. Gene expression profiling upon miR-494-3p 
overexpression allowed the identification of genes commonly downregulated both 
after microRNA overexpression and in PMF CD34+ cells. Among them, suppressor of 
cytokine signaling 6 (SOCS6) was confirmed to be a miR-494-3p target by luciferase 
assay. Western blot analysis showed reduced level of SOCS6 protein as well as STAT3 
activation in miR-494-3p overexpressing cells. Furthermore, transient inhibition 
of SOCS6 expression in HSPCs demonstrated that SOCS6 silencing stimulates 
megakaryocytopoiesis, mimicking the phenotypic effects observed upon miR-494-3p 
overexpression. Finally, to disclose the contribution of miR-494-3p upregulation to 
PMF pathogenesis, we performed inhibition experiments in PMF HSPCs, which showed 
that miR-494-3p silencing led to SOCS6 upregulation and impaired megakaryocyte 
differentiation.
Taken together, our results describe for the first time the role of miR-494-
3p during normal HSPC differentiation and suggest that its increased expression, 
and the subsequent downregulation of its target SOCS6, might contribute to the 
megakaryocyte hyperplasia commonly observed in PMF patients.
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INTRODUCTION
Philadelphia-negative chronic myeloproliferative 
neoplasms (MPNs) are a heterogeneous spectrum of clonal 
hematological malignancies that include polycythemia 
vera (PV), essential thrombocythemia (ET) and 
myelofibrosis, which can be primary (PMF) or secondary 
to PV or ET [1]. MPNs arise from the mutation of a single 
hematopoietic stem cell (HSC), which following clonal 
expansion leads to the overt clinical phenotype [2, 3]. 
While PV is mainly characterized by an overproduction 
of erythrocytes, ET and PMF patients show increased 
numbers of dysplastic megakaryocytes in the bone 
marrow (BM) [4, 5]. In addition, in PMF patients the 
BM hematopoietic tissue is progressively substituted by 
extracellular matrix and fibroblasts over the course of the 
disease, eventually resulting in BM fibrosis and failure [5]. 
In particular, megakaryocytes (MKs) have been shown to 
be mainly responsible for the overproduction of various 
cytokines that drive the formation of the fibrous scar [6].
Despite the clinical heterogeneity of MPN patients, 
PV, ET and PMF share common genomic lesions. The 
JAK2V617F somatic mutation occurs in PMF and ET 
and almost all of PV patients, while mutations in the 
thrombopoietin receptor gene, MPL, and the calreticulin 
gene, CALR, are frequent in ET and PMF patients [7–10]. 
Nevertheless, triple-negative patients, who do not carry 
any of the three “driver” mutations, represent almost 10% 
of ET and PMF cases. In addition, several other identified 
lesions (i.e. loss-of-function mutations in EZH2, ASXL1, 
TET2, JARID2) are less frequent and usually co-occur 
alongside the afore-mentioned hits [11].
Although analysis of the pathogenetic role of such 
mutations has been a topic of extensive research, none 
of the genomic lesions described is able alone to entirely 
explain all the pathological features observed in PMF. In 
fact, fewer studies address the importance of aberrantly 
expressed coding and non-coding RNAs that may affect 
the behavior of mutant HSCs. Of note, several gene 
expression profiling studies highlighted the central role of 
the activation of the JAK/STAT pathway in the disease 
pathogenesis, in keeping with previous observations 
reporting the activation of this signaling pathway induced 
by the three “driver” mutations (i.e. JAK2, MPL and 
CALR mutations) [12–14]. Indeed, Rampal and colleagues 
demonstrated that MPN patients display a transcriptional 
signature consistent with the activation of JAK2 signaling 
regardless of their mutational status [15]. Furthermore, 
non-coding RNA altered expression has already been 
reported in MPN patients in both granulocytes and 
hematopoietic stem and progenitor CD34+ cells (HSPCs) 
[16–20]. Recently, our group has shown that HSPCs from 
PMF patients aberrantly express several microRNAs 
(miRNAs), which cooperate to fine tune the expression 
of a number of target mRNAs. In particular, integrative 
analysis of dysregulated miRNAs and mRNAs allowed 
the identification of several aberrantly regulated miRNA-
mRNA target pairs organized in complex interaction 
networks where either different miRNAs contribute to 
regulate the expression of a particular gene, or a single 
miRNA can target a high number of mRNAs [21].
Here we focus our attention on miR-494-3p, which 
is upregulated in PMF HSPCs and is predicted to target the 
highest number of aberrantly expressed targets, among all 
the upregulated miRNAs. We describe for the first time 
the biological function of miR-494-3p in normal HSPC 
differentiation, demonstrating that its enforced expression 
leads to increased production of megakaryocytic cells and 
providing evidence that its phenotypic effects are mediated 
by SOCS6 downregulation. Finally, we show that miR-
494-3p silencing in PMF HSPCs affects MK production.
Collectively, our data highlight miR-494-3p as a 
key player in normal HSPC differentiation and suggest 
that the deregulation of miR-494-3p/SOCS6 axis might 
act as a new pathogenetic mechanism contributing to 
the overproduction of MKs in the bone marrow of PMF 
patients.
RESULTS
miR-494-3p is upregulated in PMF HSPCs
As recently reported by our group, we performed 
miRNA and gene expression profiling of CD34+ HSPCs 
isolated from PMF patients and healthy controls [21]. 
Integrative analysis of these profiles by means of Ingenuity 
Pathway Analysis unveiled a network involving the 
most upregulated miRNAs in PMF CD34+ cells (Figure 
1A) and their common downregulated predicted targets 
(Supplementary Figure 1).
Interestingly, our study revealed the up-regulation 
of a previously poorly characterized miRNA, miR-
494-3p, in CD34+ cells from PMF patients. Of note, 
among the most upregulated miRNAs, miR-494-3p was 
associated to the highest number of downregulated target 
mRNAs (Figure 1A, Supplementary Table 1). In detail, 
out of 903 downregulated genes associated with at least 1 
overexpressed miRNA, 86 were predicted targets of miR-
494-3p, amounting to 9.5% of all miRNA-downregulated 
genes (Figure 1B; Supplementary Table 2).
miR-494-3p overexpression affects HSPC 
differentiation
In order to understand the biological role of 
miR-494-3p during hematopoietic commitment and 
differentiation, we overexpressed it in cord blood-derived 
(CB) HSPCs and assessed its biological effects by means 
of several in vitro differentiation assays.
A significant miR-494-3p overexpression was 
detected by quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) after 24, 48 and 96 hours upon 
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transfection of CD34+ cells with miR-494-3p miRNA 
mimic (mimic-494), as depicted in Figure 2A.
Interestingly, flow cytometry evaluation of the 
co-expression of the CD34 and CD38 antigens in cells 
cultured in multilineage conditions revealed that the more 
immature CD34+/CD38- cell fraction was significantly 
expanded in mimic-494 sample compared to the control at 
96 hours after transfection. Furthermore, we also observed 
the amplification of the CD34+/CD38+ population at the 
expense of the more mature CD34-/CD38+ cell fraction, 
as demonstrated by the increase in the percentage 
and absolute cell number of double positive fraction 
(Figure 2B).
Moreover, in order to study the influence of miR-
494-3p overexpression on HSPC differentiation towards 
the myeloid lineage, we measured the expression of 
several markers in transfected cells cultured in the 
presence of human serum (HS), monitoring the expression 
levels of CD14 and CD163 for monocyte/macrophage 
differentiation and CD15, CD66b and MPO expression for 
granulocyte differentiation. As shown in Figure 2C, miR-
494-3p overexpression does not have any influence on the 
cell fraction expressing either monocyte or granulocyte 
specific antigens. Since the presence of HS inhibits 
erythroid and MK differentiation of HSPCs in vitro, we 
also explored the effects of miR-494-3p overexpression 
on erythroid and MK differentiation, in multilineage 
culture conditions in the presence of a serum substitute, by 
assessing the expression of an erythroid marker (GPA) as 
well as a megakaryocytic marker (CD41). Flow cytometry 
analysis revealed that an increased fraction of CD41+ cells 
was associated with miR-494-3p overexpression, while 
no statistically significant differences in GPA expression 
were observed (Figure 2D). Accordingly, methylcellulose-
based clonogenic assays did not show significant 
differences in myeloid or erythroid colonies (CFU-G, 
CFU-M, CFU-GM, BFU-E, CFU-E) upon miR-494-
3p overexpression (Figure 2E). Therefore, these results 
suggest that miR-494-3p overexpression in CD34+ cells 
promotes megakaryocytopoiesis, while it does not affect 
differentiation towards myeloid and erythroid lineages in 
multilineage culture conditions.
Then, in order to better characterize the role 
of miR-494-3p in MK differentiation, we performed 
overexpression experiments in CD34+ cells cultured 
in MK unilineage culture conditions. Again, the 
immunophenotype confirmed that the percentage of cells 
expressing CD41 or the late MK antigen CD42b were 
significantly higher in mimic-494 samples (Figure 3A & 
3B). Furthermore, flow cytometry analysis indicated that 
the percentage of CD41+/CD42b+ expressing cells, which 
are late MKs, were significantly higher in miR-494-3p 
overexpressing cells while no changes in the percentage 
of the CD41+/CD42b- fraction were detected (Figure 
3C). Accordingly, upon miR-494-3p overexpression, 
morphological analysis showed an expansion of the MK 
lineage, as demonstrated by the increase of precursors 
and hyperdiploid megakaryocytic cells (Figure 3D). 
Additionally, to check whether miR-494-3p could exert 
an effect also on early stages of MK commitment we 
Figure 1: miR-494-3p is overexpressed in PMF CD34+ cells. A. Line graph showing the most upregulated miRNAs in PMF 
CD34+ cells defined as showing more than 2-fold increase in the microarrays (false discovery rate<0.05) and more than 5-fold increase 
in quantitative reverse transcription polimerase chain reaction (qRT-PCR) (p-value<0.05). qRT-PCR analysis was performed in CD34+ 
cells on a cohort of 10 PMF patients and 8 healthy donors, as reported in our previous work (p<0.05) [21]. The table at the bottom of the 
graph represents the number of predicted downregulated targets for each miRNA in PMF CD34+ cells according to integrative analysis 
of gene and miRNA expression profiles. B. Venn diagram displaying the number of PMF downregulated genes targeted by at least one 
overexpressed miRNA and the number of miR-494-3p predicted targets. Abbreviations: FC, fold change.
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Figure 2: Effect of miR-494-3p on HSPCs differentiation. A. Expression levels of miR-494-3p in CB CD34+ cells were evaluated 
24, 48 and 96 hours after the last nucleofection by means of qRT-PCR. Data are reported as RQ mean ± S.E.M of 5 independent experiments. 
Results were normalized to mimic-NegCTR sample and U6 was selected as endogenous control. B. Subpanels i and ii represent statistical 
analysis of flow cytometry evaluation of CD34 and CD38 protein expression in CB CD34+ cells cultured in multilineage conditions in the 
presence of HS at 96 hours upon mimic nucleofection (n=2). Subpanel iii shows the flow cytometry analysis of a representative experiment. 
Subpanel iv represents the absolute numbers of cells belonging to the three different populations: CD34+/CD38-, CD34+/CD38+ and 
CD34-/CD38+. Absolute cell numbers were calculated, according to the percentage of cells for each population, starting from the average 
total cell number in each sample. C-D. Flow cytometry analysis of expression of monocytic (CD14, CD163), granulocytic (CD15, CD66b, 
MPO), megakaryocytic (CD41) and erythroid (GPA) differentiation markers in CB CD34+ cells overexpressing miR-494-3p maintained 
in multilineage conditions in the presence of HS (C) or the serum substitute BIT 9500 (D) at day 11 of cell culture. (n=3) E. Results of 
the statistical analysis of methylcellulose clonogenic assay of CB CD34+ cells overexpressing miR-494-3p. Cells were plated 24 hours 
after mimic nucleofection and colonies were scored at day 14 (n=3). Results are reported as mean ± S.E.M. *, p≤0.05 Abbreviations: CFU, 
colony-forming unit; BFU, burst-forming unit; E, erythroid; GM, granulo-monocyte; G, granulocyte; M, monocyte; GEMM, granulocyte, 
erythrocyte, macrophage, megakaryocyte.
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evaluated the co-expression of the stem/progenitor marker 
CD34 and the MK marker CD41. Flow cytometry analysis 
indicated that miR-494-3p overexpression led to the 
expansion of the double-positive population at days 4 and 
6 of liquid culture, while the percentage of CD34+/CD41- 
cells was decreased accordingly (Figure 3E). Collagen-
based clonogenic assay confirmed these results showing 
a significant increase in the percentage of medium-sized 
MK colony forming units (CFU-MK Medium), which 
arise from more primitive MK progenitors. Of note, the 
percentage of small CFU-MK, which derive from more 
mature MK progenitors, were similarly increased after 
miR-494-3p overexpression (Figure 3F). As a whole, these 
results demonstrated that miR-494-3p overexpression 
promotes megakaryocytopoiesis acting both on early 
and late stages of the differentiation process in normal 
CD34+ cells.
miR-494-3p-overexpression alters HSPC 
gene expression
To better characterize the molecular mechanisms 
underlying the effects of miR-494-3p on HSPC 
differentiation, we carried out a microarray-based gene 
expression analysis at 24 hours after the last nucleofection 
to compare miR-494-3p overexpressing cells vs control 
cells. The list of 196 differentially expressed transcripts is 
showed in Figure 4 and Supplementary Table 3.
Among the downregulated genes, suppressor of 
cytokine signaling 6 (SOCS6) resulted to be the miR-
494-3p predicted target associated to the most favorable 
context+ score according to TargetScanHuman database 
(Supplementary Table 4). Intriguingly, SOCS6 was also 
downregulated in PMF HSPCs, which showed miR-
494-3p upregulation as well [21]. Moreover, SOCS6 is 
a key player in the negative regulation of the JAK/STAT 
signaling pathway [22], whose constitutive activation 
is one of the most important molecular mechanisms 
underlying MPN pathogenesis. These observations, along 
with our findings, prompted us to further investigate the 
interaction between miR-494-3p and SOCS6 and their 
possible role in HSPC differentiation.
SOCS6 is a miR-494-3p target
SOCS6 encodes for a protein that belongs to the 
suppressor of cytokine signaling protein family, a group of 
molecules involved in the negative regulation of cytokine 
and of growth factor receptor signaling. In particular, 
SOCS6 regulates cytokine signaling by interfering with 
transduction pathways activated by several hematopoietic 
receptor tyrosine kinases, such as KIT (Mast/stem cell 
growth factor receptor Kit) and FLT3 (Receptor-type 
tyrosine-protein kinase FLT3), leading to impaired 
activation of members of the MAPK pathway [23, 24]. 
qRT-PCR results showed a significant reduction of SOCS6 
mRNA levels in miR-494-3p overexpressing HSPCs 24 
hours after the last nucleofection. Similarly, the mRNA 
levels of phosphatase and tensine homolog (PTEN), 
chosen as positive control as it is a known miR-494-3p 
target [25], was decreased in mimic-494 samples, while 
the expression of jumonji and AT-rich interaction domain 
containing 2 (JARID2), which was selected as a negative 
control, was not changed (Figure 5A).
As shown in Figure 5B, SOCS6 3' untraslated region 
(3'UTR) displays three putative miRNA recognition 
elements (MRE), as reported by the target prediction tools 
TargetScanHuman and microRNA.org (www.microrna.
org). To validate the direct interaction between miR-494-
3p and SOCS6, we employed a reporter vector where the 
Firefly luciferase gene sequence is located upstream of 
the wild-type 3’UTR sequence of SOCS6 (SOCS6 wt). 
As negative controls, we used three different reporter 
constructs containing a 3 nucleotide substitution in each 
of the MREs present in SOCS6 3'UTR (i.e. SOCS6 mut01, 
SOCS6 mut02, SOCS6 mut03) and one reporter plasmid 
containing JARID2 3'UTR sequence (JARID2 wt). 3'UTR 
luciferase reporter assays performed with these vectors 
showed a statistically significant reduction in normalized 
luciferase activity in K562 cells co-nucleofected with 
miR-494-3p miRNA mimic and SOCS6 wt reporter 
construct. This reduction was comparable to that observed 
in the positive control sample transfected with the plasmid 
containing PTEN 3'UTR [26] (Figure 5C). Consistently, 
miR-494-3p failed to induce a significant reduction in 
normalized luciferase activity when K562 cells were co-
nucleofected with SOCS6 3'UTR mutated sequences or 
JARID2 3'UTR (Figure 5C).
In order to confirm the downregulation of SOCS6 
protein after miR-494-3p overexpression, we performed 
western blot analysis both in K562 and CB CD34+ cells. 
While SOCS6 protein was reduced only 48 hours after 
mimic nucleofection in K562 cells (Figure 6A), SOCS6 
protein expression decreased 24, 48 and 96 hours post 
electroporation in CB CD34+ cells, further supporting 
the hypothesis that SOCS6 is a direct target of miR-494-
3p (Figure 6B). Since SOCS6 has already been shown 
to act as a negative regulator of signal transducer and 
activator of transcription 3 (STAT3) signaling [22], 
we wondered if miR-494-3p overexpression was able 
to interfere with STAT3 activity. In order to answer 
this question, we performed western blot analysis, 
which revealed that miR-494-3p overexpressing cells 
showed reduced levels of SOCS6 protein as well as 
higher levels of phospho-STAT3, as depicted in Figure 
6C. Altogether, these results demonstrated the direct 
interaction between miR-494-3p and SOCS6 3'UTR and 
suggested that miR-494-3p overexpression interferes 
with STAT3 signaling by inhibiting SOCS6 expression 
in CD34+ HSPCs.
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Figure 3: miR-494-3p overexpression affects MK differentiation of HSPCs. A-B. Bar-graphs represent the statistical analysis 
of the flow cytometry evaluation of CD41 (A) and CD42b (B) cell markers in CB CD34+ cells overexpressing miR-494-3p. Marker 
expression was assessed at days 3, 5, 8, 10 and 12 of serum-free MK unilineage cell culture (n=3). C. Flow cytometry analysis of co-
expression of CD41 and CD42b surface antigens at days 8 and 10 of MK unilineage culture after mimic nucleofection in CB CD34+ 
cells (n=3). D. Representative morfological analysis of mimic-NegCTR (i-iii) and mimic-494 (ii-iv) samples after May-Grünwald-Giemsa 
staining at days 8 and 10 of MK unilineage culture. Magnification, x400. Scale bar: 100 μm. E. Subpanel i represents the statistical 
analysis of flow cytometry analysis of co-expression of CD34 and CD41 surface antigens at days 4 and 6 post mimic electroporation in 
serum free multilineage culture (n=3). Subpanel ii shows corresponding dot plot graphs of a representative experiment. F. Results of the 
statistical analysis of collagen-based clonogenic assay of CB CD34+ cells overexpressing miR-494-3p. Cells were seeded in semisolid 
culture medium 24 hours after the last nucleofection and colonies were scored after 11 days (n=3). Results are reported as mean ± S.E.M. 
**, p≤0.01; *, p≤0.05 Abbreviations: CFU, colony-forming unit; MK, megakaryocyte; MIX, mixed; nonMK, other than megakaryocyte.
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SOCS6 silencing supports MK 
differentiation of HSPCs
Next, we investigated whether SOCS6 
downregulation was able to phenocopy the effects 
on megakaryocytopoiesis seen upon miR-494-3p 
overexpression in CD34+ cells. To this aim, we inhibited 
SOCS6 expression by transfecting CD34+ cells with 
either SOCS6 small interfering RNA (siRNA) (siSOCS6 
sample) or negative control siRNA (siNeg CTR). Real-
Time qRT-PCR analysis, performed 24 hours after 
treatment, confirmed the downregulation of mRNA levels 
in siSOCS6 samples compared to controls (RQ ± S.E.M, 
0,4506 ± 0,0430, p<.01).
Flow cytometry analysis and methylcellulose-
based clonogenic assay demonstrated that SOCS6 
downregulation did not affect myeloid or erythroid 
differentiation of HSPCs cultured in multilineage 
conditions (data not shown), in agreement with the results 
obtained upon miR-494-3p overexpression. Since miR-
Figure 4: Microarray analysis upon miR-494-3p overexpression. A. Hierarchical clustering of mimic-NegCTR (mimic Neg 
CTR) and mimic-494 (mimic miR-494) samples based on the list of 196 differentially expressed transcripts.
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Figure 5: Validation of miR-494-3p/SOCS6 3’UTR interaction. A. Evaluation of SOCS6, PTEN and JARID2 mRNA expression 
in CB CD34+ cells overexpressing miR-494-3p by means of qRT-PCR. Transcript levels were assessed 24, 48 and 96 hours after the last 
nucleofection. Results were normalized to mimic-NegCTR sample and 18s rRNA was selected as endogenous control. Data are reported 
as RQ mean ± S.E.M of 3 independent experiments. B. Representation of the three miR-494-3p predicted binding sites in SOCS6 3’UTR 
sequence as reported by TargetScanHuman and microRNA.org (www.microrna.org). The seed region of the miRNA is highlighted. C. The 
bar graph represents the results of 3’UTR luciferase reporter assay performed in K562 cell line. Normalized luciferase activity in cells co-
nucleofected with miR-494-3p miRNA mimic or miRNA mimic Negative Control and the indicated 3’UTR reporter vector is represented. A 
sample nucleofected with plasmid containing PTEN 3’UTR was included as positive control, while mutated SOCS6 3’UTR and wild-type 
JARID2 3’UTR were selected as negative controls. (n=3). Results are reported as mean ± S.E.M. **, p≤0.01; *, p≤0.05
Figure 6: miR-494-3p overexpression reduces SOCS6 expression and enhances STAT3 phosphorilation. A-B. Western 
blot analysis of SOCS6 protein levels in whole cell lysates from K562 (A) and CB CD34+ (B) cells overexpressing miR-494-3p at different 
time-points after mimic nucleofection. SOCS6 protein levels in miR-494-3p overexpressing cells were compared with control samples 
nucleofected with mimic Negative Control (Neg CTR). β-actin was included as loading control while PTEN was selected as positive 
control. C. Immunoblots representing phospho-STAT3 increase in CB CD34+ cells overexpressing miR-494-3p compared with negative 
control (Neg CTR) 48 and 96 hours after nucleofection. β-actin was included as loading control.
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494-3p overexpression promoted MK differentiation in 
CD34+ cells in unilineage MK cultures, we tested whether 
SOCS6 silencing could reproduce the same effects. Flow 
cytometry analysis revealed that SOCS6 silencing was 
able to induce a significant increase in the percentage 
of both CD41+ and CD42b+ cell fractions (Figure 7A 
& 7B). Interestingly, we highlighted an expansion of 
CD41+/CD42b+ population in siSOCS6 samples, while 
no variation in CD41+/CD42b- cell fraction was observed 
(Figure 7C). Accordingly, morphological analysis showed 
that SOCS6-silenced CD34+ cells generated a higher 
number of MK precursors compared with the control 
(Figure 7D). Moreover, SOCS6 silencing caused the 
expansion of CD34+/CD41+ MK progenitors (Figure 7E), 
coupled to the increase of the percentage of MK colonies 
(Figure 7F). Collectively, these results demonstrated that 
SOCS6 silencing is able to promote MK differentiation 
of HSPCs, in agreement with the results obtained in miR-
494-3p overexpression experiments.
Furthermore, in order to confirm the role of miR-
494-3p/SOCS6 axis in MK differentiation, we analyzed 
their expression levels in CD34+ cells maintained in 
megakaryocytic unilineage culture conditions. qRT-
PCR analysis showed steady upregulation of miR-494-
3p expression levels during MK differentiation, which 
was associated with a reduction of SOCS6 mRNA 
(Figure 7G).
miR-494-3p inhibition impairs MK 
differentiation of PMF CD34+ cells
Finally, to gain further insight into the role of miR-
494-3p/SOCS6 axis in the pathogenesis of PMF, we 
looked for a possible correlation between miR-494-3p 
and SOCS6 expression levels in our dataset of 42 PMF 
samples and 31 healthy donors. Interestingly, we found 
that SOCS6 expression was negatively correlated to miR-
494-3p expression (r = −0.57, p = 1.12 × 10−7) (Figure 
8A) and western blot analysis confirmed SOCS6 protein 
downregulation in PMF CD34+ cells (Figure 8B).
Furthermore, in order to investigate if the 
downregulation of miR-494-3p could reduce the 
production of MKs in PMF CD34+ cells, we transfected 
them with a miR-494-3p inhibitor (miR-494 Inhib) 
or a negative control inhibitor (Neg CTR Inhib). The 
downregulation of miR-494-3p (Figure 8C) caused the 
increase in SOCS6 and PTEN expression both at mRNA 
and protein levels (Figure 8D & 8E).
Flow cytometry analysis showed that the 
downregulation of miR-494-3p was able to reduce both 
the CD41+ and CD42b+ fractions (Figure 8F & 8G), 
whereas a reduction in MK precursors was observed 
by morphological analysis after miR-494-3p inhibition 
(Figure 8H). Finally, we observed a statistically significant 
decrease in the percentage of MK colonies in miR-494-3p 
Inhib sample (Figure 8I).
Altogether these results demonstrate that miR-
494-3p inhibition in PMF CD34+ cells led to SOCS6 
upregulation and impairs MK differentiation suggesting 
the involvement of miR-494-3p/SOCS6 axis in PMF 
pathogenesis.
DISCUSSION
A growing body of experimental evidence has been 
supporting a key role for miRNAs in tumorigenesis, both 
for solid cancers and for hematological malignancies 
[27, 28]. Recently, our group showed how miRNAs may 
contribute to the pathogenesis of PMF. In particular, we 
analyzed and integrated gene and miRNA expression 
profiles in PMF CD34+ cells to uncover networks of 
miRNA-mRNA interaction. Biologically relevant network 
nodes may be composed either by deregulated genes 
targeted by many aberrantly expressed miRNAs or by 
single miRNAs targeting multiple genes. While the first 
type of network highlights the relevance of the targeted 
gene, the latter emphasizes the role of the miRNA as a 
central player in the pathogenetic mechanisms. Thus, we 
sought to find an aberrantly expressed miRNA targeting 
many genes in our dataset [21].
In the present study, we found a network involving 
the most upregulated miRNAs in PMF CD34+ cells and 
their common downregulated predicted targets. Among 
the most upregulated miRNAs, miR-494-3p emerges as 
being associated to the highest number of downregulated 
target mRNAs. In particular, 86 DEGs were found to 
be miR-494-3p predicted targets in silico. Supporting a 
possible role for miR-494-3p in PMF pathogenesis, among 
its 86 downregulated targets there are several genes that 
have been described as tumor suppressor genes (CUL3 
[29], KLF11 [30], TRAF3 [31] and SOCS6 [32]) as 
well as genes whose low expression has been associated 
with the development of myeloid malignancies such 
as ARID4B [33], PURB [34], ELF2 [35] and RAD23B 
[36]. Furthermore, among the miR-494-3p downregulated 
targets, NR2C1, WIP1, HLF and HMGB3 encode for 
proteins involved in the regulation of hematopoietic stem 
cell self-renewal and differentiation [37–40]. However, the 
role of miR-494-3p in tumorigenesis has generally been 
reported as controversial. Nonetheless, several authors 
have described it as an oncomiR in several neoplastic 
contexts, such as in retinoblastoma [41], hepatocellular 
carcinoma [42] and in non-small cell lung cancer [25]. In 
hematopoietic malignancies, the overexpression of miR-
494-3p has been reported in various forms of lymphomas 
such as follicular lymphoma [43], classical Hodgkin 
lymphoma [44], nasal natural killer cell lymphoma [45]. 
More recently, the overexpression of miR-494-3p in 
CD34+ cells from PMF patients has been described by 
our group [21]. Therefore, we wondered if miR-494-3p 
could be able to alter HSPC fate decisions and thus could 
be involved in PMF pathogenesis.
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Figure 7: SOCS6 silencing affects MK differentiation of HSPCs. A-B. Results of the statistical analysis of the percentages 
of CD41+ and CD42b+ cells evaluated by means of flow cytometry upon SOCS6 silencing in CB CD34+ cells. Marker expression was 
assessed at days 3, 5, 8, 10 and 12 in cells cultured in serum-free MK unilineage conditions (n=4). C. Flow cytometry analysis of cells co-
expressing CD41 and CD42b surface antigens at days 8 and 10 of MK unilineage culture (i) (n=4). Sub-panel ii displays flow cytometry 
graphs of a representative experiment. D. Morphological analysis of siNeg CTR (i-iii) and siSOCS6 (ii-iv) samples after May-Grünwald-
Giemsa staining at days 8 and 10 of MK unilineage culture in a representative experiment. Magnification, x400. Scale bar: 100 μm. E. 
Results of flow cytometry analysis of cells expressing both CD34 and CD41 surface antigens at days 3 and 5 post electroporation in serum 
free multilineage culture (n=4). F. Results of the statistical analysis of collagen-based clonogenic assay of CB CD34+ cells upon SOCS6 
silencing. Cells were seeded in semisolid culture medium 24 hours after the last nucleofection and colonies were scored after 11 days (n=3). 
G. miR-494-3p and SOCS6 expression kinetic during MK differentiation. Gene and miRNA expression levels were normalized to cells 
cultured in the presence of HS for 24 hours after purification (HS 24 sample). 18s rRNA and U6 were used as endogenous controls for gene 
and miRNA expression evaluation respectively (n=4). Results are reported as mean ± S.E.M. **, p≤0.01; *, p≤0.05 Abbreviations: CFU, 
colony-forming unit; MK, megakaryocyte; MIX, mixed, nonMK, other than megakaryocyte.
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Figure 8: miR-494-3p inhibition impairs MK differentiation of PMF CD34+ cells. A. Scatter plot representing the correlation 
between miR-494-3p and SOCS6 expression levels according to the microarray analysis in our initial dataset of 42 PMF samples and 31 
healthy donors. The Spearman rank correlation coefficient (r) was used to measure and identify the degree of linear dependence between 
the ranked variables (r = −0.57, p = 1.12 × 10−7). Green circles = PMF CD34+ cells, Red triangles = PB CD34+ cells, Blue squares = BM 
CD34+ cells. Abbreviations: PMF, primary myelofibrosis; PB, peripheral blood; BM, bone marrow; CTR, control. B. Western blot analysis 
of SOCS6 protein levels in PMF CD34+ cells compared to CB CD34+ cells. β-actin was included as loading control. C-D. Expression 
levels of miR-494-3p, SOCS6, and PTEN in PMF CD34+ cells after miRNA inhibition evaluated by means of qRT-PCR. Data are reported 
as RQ mean ± S.E.M (n=3). E. Immunoblots representing SOCS6 protein levels in whole cell lysates from PMF CD34+ cells after miR-
494-3p inhibition. SOCS6 protein levels were evaluated 24, 48 and 96 hours after miR-494-3p inhibitors nucleofection and were compared 
with control samples electroporated with Negative Control inhibitors (NegCTR). β-actin was included as loading control while PTEN was 
selected as positive control. F-G. Results of flow cytometry analysis of the percentages of CD41+ (F) and CD42b+ (G) cells evaluated at 
days 3, 5, 8, 10 and 12 in serum-free MK unilineage conditions (n=3). H. Morfological analysis of Neg CTR Inhib (i) and miR-494 Inhib 
(ii) samples after MGG staining at day 9 of MK unilineage culture in a representative experiment. Magnification, x400. Scale bar: 100 μm. 
I. Results of the statistical analysis of collagen-based clonogenic assay of PMF CD34+ cells upon miR-494-3p inhibition. Cells were seeded 
in semisolid culture medium 24 hours after the last nucleofection and colonies were scored after 11 days (n=3). Results are reported as mean 
± S.E.M. *, p≤0.05. Abbreviations: CFU, colony-forming unit; MK, megakaryocyte; MIX, mixed; nonMK, other than megakaryocyte.
Oncotarget21391www.impactjournals.com/oncotarget
To this end, we performed miR-494-3p 
overexpression experiments in normal CD34+ cells 
demonstrating that its upregulation enforces MK 
differentiation while myeloid or erythroid differentiation 
are not affected. In particular, immunophenotypic 
and morphological analysis revealed that miR-494-
3p overexpression promotes megakaryocytopoiesis in 
HSPCs leading to the expansion of both early and late MK 
precursors in liquid and semisolid culture.
Therefore, to go even deeper into the molecular 
mechanisms by which miR-494-3p might be able to 
support megakaryocytopoiesis, we performed gene 
expression profiling of CD34+ cells overexpressing 
miR-494-3p, to specifically find downregulated genes 
predicted as putative target of this miRNA. Since we 
hypothesized that miR-494-3p upregulation might 
contribute to the aberrant megakaryocytopoiesis in PMF 
patients, we sought deregulated genes that were similarly 
downregulated both after miR-494-3p overexpression and 
in PMF CD34+ cells. Among them, SOCS6 was selected 
since it was predicted with particularly high likelihood to 
be a target of miR-494-3p according to TargetScanHuman 
prediction tool.
In order to confirm the predicted interaction, we 
performed luciferase reporter assay and western blot 
analysis, which demonstrated that SOCS6 is a real target 
of miR-494-3p in hematopoietic cells.
SOCS6 belongs to the family of suppressor 
of cytokine signaling (SOCS) proteins which act as 
negative regulators of cytokine and growth factor 
receptor signaling [46]. In particular, SOCS6 has been 
reported to interfere with the signal transduction of key 
hematopoietic receptor tyrosine kinases. Indeed, SOCS6 
associates to KIT and FLT3 upon ligand stimulation to 
induce receptor ubiquitination with consequent reduction 
of their protein levels, ultimately leading to the impaired 
activation of ERK1/2 and p38 MAP kinases [23, 24, 47]. 
Furthermore, SOCS6 regulates the JAK/STAT signaling 
pathway by decreasing STAT3 nuclear protein levels and 
by inhibiting STAT3 activation reducing the amount of 
phosphorilated protein [22, 48]. Of particular interest, 
TPO promotes megakaryocytopoiesis in HSPCs through 
the binding to its receptor TPO-R (Thrombopoietin 
receptor) that leads to the activation of JAK2 protein 
kinase, which in turn phosphorilates and activates STAT3 
[49]. Of further relevance, constitutive activation of the 
JAK/STAT pathway caused by the presence of mutations 
in MPL (i.e. the gene encoding for TPO-R) and CALR 
genes represents an important pathogenetic event in PMF 
onset and development [13, 14, 50]. Since miR-494-3p 
inhibits SOCS6, which is a negative regulator of STAT3, 
a key player in megakaryocytopoiesis, we therefore 
hypothesized that STAT3 would be more active when 
miR-494-3p expression is upregulated. In keeping with 
these observations, our results demonstrated that miR-494-
3p overexpression in CD34+ HSPCs indeed reinforced 
STAT3 signaling by reducing SOCS6 expression, thus 
increasing the amount of phospho-STAT3. Altogether, 
these observations compelled us to investigate the role of 
SOCS6 in normal CD34+ cell differentiation.
First, we silenced SOCS6 expression in CD34+ 
cells by using a siRNA-based approach in order to 
establish if SOCS6 silencing might reproduce the effects 
of miR-494-3p overexpression. Thus, we inhibited 
SOCS6 expression during the first days of liquid culture, 
corresponding to the early stages of HSPC commitment in 
vitro. Immunophenotypic and morphological analysis, as 
well as collagen-based clonogenic assays, demonstrated 
that SOCS6 downregulation phenocopies the same 
effects on CD34+ cell differentiation observed in miR-
494-3p overexpression experiments. Indeed, SOCS6 
downregulation supported megakaryocytopoiesis but had 
no effects on myeloid or erythroid differentiation. Our 
results showed also that SOCS6 silencing affected both 
early and late stages of MK differentiation. Furthermore, 
we analyzed miR-494-3p and SOCS6 expression 
during MK differentiation of CD34+ cells. Analysis 
of the expression kinetics showed that miR-494-3p is 
upregulated while SOCS6 mRNA is downregulated when 
normal CD34+ cells are forced to megakaryopoiesis in 
vitro. Altogether, our results demonstrated that miR-494-
3p acts through the downregulation of its target SOCS6 
and promotes MK differentiation in vitro. Finally, to 
confirm that the newly described miR-494-3p/SOCS6 axis 
may play role in the pathogenesis of PMF, we highlighted 
the negative correlation between miR-494-3p and SOCS6 
expression in CD34+ PMF samples. Furthermore, we 
demonstrated that the silencing of miR-494-3p in PMF 
CD34+ cells, which overexpress this miRNA, induced 
SOCS6 upregulation and impaired MK overproduction.
One of the main features characterizing the bone 
marrow of PMF patients is an excessive number of MKs, 
which have been proposed to be the key cells leading 
to the fibrotic phenotype through a cytokine storm [6]. 
Therefore, it is of primary importance to explore the 
biological mechanisms that drive this MK hyperplasia. 
Many and different somatic mutations have been reported 
to be carried from PMF patients, who may have complex 
combination of such lesions. Analysis of miRNA and 
mRNA expression is therefore important as it may help 
to find common pathways that are deregulated and shared 
by these subgroups of patients. Integrative analysis of 
aberrantly expressed miRNAs and genes in CD34+ cells 
and functional validation experiments highlighted a 
possible role for miR-494-3p and its target SOCS6 in the 
pathogenesis of PMF.
Overall, these data suggest that miR-494-
3p/SOCS6 axis is an important player during the 
physiological differentiation of HSPCs due to its ability 
to enforce the lineage commitment decision towards 
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megakaryocytopoiesis. Of particular interest, our results 
support the hypotesis that miR-494-3p altered expression 
in PMF CD34+ cells contributes to the development of 
MK hyperplasia through the downregulation of SOCS6.
MATERIALS AND METHODS
Ethics statement
Human CD34+ cells were purified upon donor’s 
informed written consent from umbilical cord blood 
samples, collected after normal deliveries, according to 
the institutional guidelines for discarded material.
Primary myelofibrosis CD34+ cells were 
isolated from the peripheral blood (PB) of 3 patients 
diagnosed with PMF in a typical fibrotic phase of the 
disease according to the recently updated World Health 
Organization (WHO) criteria [1]. All subjects provided 
informed written consent, and the study was performed 
under the local Institutional Review Board’s approved 
protocol (Florence: approval date: April 22, 2011, 
approval file number # 2011/ 0014777; Pavia: approval 
date: February 24, 2011, file number #174). The study was 
conducted in accordance with the Declaration of Helsinki.
Gene and miRNA expression profiles 
integrative analysis
Gene and miRNA expression profiles of CD34+ 
cells from 42 PMF and 31 healthy donors (n=15 BM, 
n=16 PB) were previously reported and submitted to a 
public repository (GEO series GSE41812 and GSE53482) 
[21]. Differentially expressed genes (DEGs) and miRNAs 
(DEMs) were here selected by using the analysis of 
variance (ANOVA) module included in the Partek GS 
package. In particular, we considered as differentially 
expressed all the probe sets with a fold change contrast 
(FC) ≥1.5 and false discovery rate (q value) <0.05 for both 
genes and miRNAs in the pairwise comparison of PMF 
vs controls.
In silico integrative analysis was performed by 
using QIAGEN's Ingenuity Pathway Analysis software 
(Ingenuity Systems; Redwood City, CA, http://www.
ingenuity.com/ingenuity), as previously described [21].
CD34+ cell purification
Human CD34+ cells were purified from CB or PB 
samples from PMF patients as previously described [21]. 
Purified CD34+ cells were cultured in 24-well plates 
at 5×105/ml in Iscove’s modified Dulbecco’s medium 
(IMDM, Euroclone) containing 20% HS (Bio-Whittaker), 
interleukin-3 (IL-3) (10 ng/ml), interleukin-6 (IL-6) (10 
ng/ml), thrombopoietin (TPO) (20 ng/ml), stem cell 
factor (SCF) (50 ng/ml) and Flt3-ligand (FLT3L) (50 ng/
ml), (all from Miltenyi Biotec; Auburn, CA, USA) and 
electroporated 24 hours later.
Electroporation of CD34+ cells
Human CD34+ cells were nucleofected by using 
the 4DNucleofectorTM System (Lonza) as previously 
reported [21], with minor changes. With regards to miR-
494-3p overexpression experiments, each sample was 
nucleofected twice, once every 24 hours, with mirVanaTM 
miRNA mimics (Thermo Fisher Scientific Inc) starting 
from the day upon CD34+ cell purification. For each 
electroporation, 3-4x105 CD34+ cells were nucleofected 
with 3 μg (0,21 nmol) of mirVanaTM miR-494-3p miRNA 
mimic (mimic-494) using the preset pulsing program 
DS112. To account for nonspecific effects given by 
electroporation of small RNAs, CD34+ cells transfected 
with mirVana miRNA mimic Negative Control #1 (mimic-
NegCTR) were used as controls.
Similarly, SilencerR Select small interfering RNA 
(siRNA) (Thermo Fisher Scientific Inc) transfection 
was performed as follows [21]. Briefly, CD34+ cells 
were nucleofected 3 times, once every 24 hours, using 
3 μg of SilencerR Select siRNA against human SOCS6 
(Supplementary Table 5) or a non-targeting siRNA as 
a negative control (SilencerR Select Negative Control 
#2 siRNA; Thermo Fisher Scientific Inc) by using the 
previously mentioned electroporation protocol DS112.
For miRNA inhibition experiments, PMF CD34+ 
cells were nucleofected 3 times using the same pulsing 
protocol, once every 24 hours, with 1 μg (0,21 nmol) of in 
vivo LNATM miR-494-3p inhibitor or the same quantity of 
a scramble negative control inhibitor (Exiqon).
SOCS6 or miR-494-3p expression were analyzed 24 
hours upon the last nucleofection.
RNA extraction and qRT-PCR
Total cellular RNA was harvested from 5×104 
cells from each sample using the miRNeasy Micro RNA 
isolation kit (QIAGEN), according to the manufacturer’s 
instructions and as previously described [51].
Relative quantification (RQ) of mRNA and miRNA 
expression levels was performed as previously described 
[51]. 18S ribosomal RNA (18S rRNA) or glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were used as 
housekeeping genes for mRNA expression RQ, while 
U6 snRNA was used as housekeeping control for RQ of 
miRNA expression levels.
Gene expression profiling (GEP)
GEP was performed on RNA samples isolated 
from CD34+ cells transfected with both miR-494-3p 
miRNA mimics or miRNA mimic Negative control 
24 hours after 2 nucleofections from three independent 
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experiments. mRNA was processed as previously 
described [51]. Robust multiarray average (RMA) 
procedure was used to perform probe level normalization 
and conversion into expression values [52]. DEGs were 
then selected following a supervised approach with the 
analysis of variance (ANOVA) module supplied by the 
Partek GS. 6.6 Software Package (http://www.partek.
com). We considered as differentially expressed all the 
probesets with a fold change contrast ≥1.5 in the pairwise 
comparison between mimic-494 and mimic-NegCTR 
samples and a p-value ≤0.05.
Raw and normalized GEP data have been submitted 
to the NCBI's Gene Expression Omnibus (GEO) public 
repository (http://www.ncbi.nlm.nih.gov/geo; series 
GSE85250).
CD34+ cell-culture conditions
Liquid cultures to assess the differentiation potential 
were set up 24 hours after the last nucleofection. Briefly, 
CD34+ cells were seeded 3-5×105/mL in IMDM with 20% 
HS in order to set up a multilineage cell culture (IL-6, 10 
ng/mL; IL-3, 10 ng/mL; TPO, 20 ng/mL; SCF, 50 ng/mL; 
Flt3L, 50 ng/mL; all cytokines from Miltenyi Biotec). 
To obtain MK and erythroid differentiation in vitro, cells 
were also cultured in IMDM supplemented with 20% BIT 
9500 serum substitute (bovine serum albumin, insulin, and 
transferrin; StemCell Technologies) with the same afore-
mentioned cytokine cocktail. Unilineage cultures were set 
up by seeding 3-5×105 cells/mL in IMDM with the addition 
of 20% BIT and TPO 100 ng/mL in order to induce MK 
differentiation (Miltenyi Biotec) [51].
In order to study the expression kinetics of miR-
494-3p during MK differentiation, CD34+ cells were 
cultured in 24-well plates at a density of 3-5x105/ml in 
the same condition described above. After a first phase of 
expansion, 24 hours after purification, 5x104 cells were 
lysed for RNA extraction (HS 24h) and the remaining 
cells were seeded (5x105/ml) in MK unilineage culture 
conditions. The medium was replaced every 3 days. Cell 
differentiation was monitored by morphological analysis 
of May-Grünwald-Giemsa (MGG) stained cytospins 
and by flow cytometry analysis of differentiation marker 
expression. miR-494-3p and SOCS6 expression levels 
were detected by qRT-PCR at different time points 
(i.e. days 3, 5, 8 and 12) after seeding the cells in MK 
unilineage cultures.
Morphological and immunophenotypic analysis
Differentiation of CD34+ cells was assessed by 
morphological analysis of stained cytospins and by flow 
cytometry analysis of differentiation marker expression 
(CD34, CD38, CD66b, CD15, myeloperoxidase (MPO), 
CD14, CD163, Glycophorin A (GPA), CD41, CD42b) at 
day 3, 5, 8, 10, and 12 after the last nucleofection. The 
following monoclonal antibodies (MoAbs) were used 
for flow cytometry analysis: fluorescein isothiocyanate 
(FITC)-conjugated mouse anti-human CD34 MoAb; 
allophycocyanin (APC)-conjugated mouse anti-human 
CD34 MoAb; FITC-conjugated mouse anti-human CD66b 
MoAb; FITC-conjugated mouse anti-human CD15 MoAb; 
phycoerythrin (PE)-conjugated mouse anti-human CD14 
MoAb; APC-conjugated mouse anti-human CD163 
MoAb; PE-conjugated mouse anti-human CD42b MoAb 
(all from Miltenyi Biotech); FITC-conjugated mouse 
anti-human CD41 MoAb, and PE-conjugated mouse anti-
human GPA MoAb (all from Dako; Milano, Italia; http://
www.dako.com) and FITC-conjugated mouse anti-human 
MPO MoAb (from BD Biosciences; San Jose, CA USA). 
For the MPO intracellular staining, a previous fixation and 
permeabilization step is required, therefore we employed 
the Fix&Perm kit (ThermoFisher Scientific). After 
staining, cells were analyzed by using a BD FACSCanto 
II (BD Biosciences; San Jose, CA USA). At least 10,000 
events were counted for each sample to ensure statistical 
relevance.
Images of MGG stained cytospins were captured 
by using an Ax10scopeA1 microscope equipped with an 
AxioCam ERc 5S Digital Camera and Axion software 4.8 
(all Carl Zeiss MicroImaging Inc.; Thornwood, NY, USA). 
The images were then processed with Adobe Photoshop 
7.0 software.
Methylcellulose and collagen clonogenic assays
Clonogenic capacity of nucleofected CD34+ 
cells was assessed by setting up two different assays. 
The methylcellulose-based clonogenic assay was 
carried out by plating CD34+ cells in MethoCultTM 
GF H4434 (StemCell Technologies Inc.; Vancouver), 
as previously described [53]. In addition, MK colony 
forming units (CFU-MK) were assayed in collagen-
based medium, using a commercial MK assay detection 
kit (MegaCult-C; StemCell Technologies Inc.) as 
previously reported [54]. Briefly, 24 hours after the 
last nucleofection 2.5 x 103 CB CD34+ cells and 3.75 
x 103 PMF CD34+ cells were seeded in each chamber 
of a double-chamber slide (0.75 mL per-chamber). 
The employed medium contained: collagen (1.1 mg/
ml), bovine serum albumin (1%), bovine pancreatic 
insulin (0.01 mg/ml), human transferrin (iron-saturated) 
(0.2 mg/ml), and the following human recombinant 
cytokines: TPO (50 ng/ml), IL-3 (10 ng/ml) and IL-6 (10 
ng/ml). After 11 days of incubation at 37°C the chamber 
slides were fixed in methanol/acetone solution and 
MK colonies were stained using a primary monoclonal 
anti-CD41 (GPIIb/IIIa) antibody. MK colonies were 
identified using an alkaline phosphatase/naphthol 
detection system (all from StemCell Technologies), 
while nuclei of all the cells, regardless of their 
lineage, were counterstained with Evans Blue. CD41- 
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positive colonies were scored as CFU-MK and 
subdivided by size in small (3-21 cells), medium (21-49 
cells) and large (>50 cells) colonies which reflects the 
maturation stage of the progenitor giving rise to each 
colony.
3' untranslated region (3'UTR) luciferase 
reporter assays
Empty luciferase reporter constructs (pEZX-MT01) 
or plasmids containing wild-type and mutated full-length 
3'UTR from human SOCS6 (RefSeq NM_004232.3), 
human phosphatase and tensine homolog (PTEN) 
(RefSeq NM_000314.4) and human JARID2 (RefSeq 
NM_004973.2) transcripts were all purchased from 
Labomics (Genecopoeia; MD, USA). Further details are 
presented in Supplementary Table 6. Luciferase assay and 
its following normalization were performed as previously 
reported [21].
Western blot
Protein levels were assessed by means of Western 
Blot Analysis in both CB CD34+ cells and K562 cells 
(ATCC) overexpressing miR-494-3p, and in PMF CD34+ 
cells after miRNA inhibition. Briefly, cells were harvested 
24, 48 and 96 hours after the last nucleofection, washed 
twice with cold phosphate-buffered saline (PBS) and lysed 
in 50 mM Tris (tris(hydroxymethyl) aminomethane)-
Cl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 10 mM 
KCl, 1 mM EDTA, 20 mM NaF, 0.25% Na deoxycholate, 
5 mM dithiothreitol (DTT). Protease inhibitors (Roche, 
Indianapolis, IN, USA Complete, catalog #1697498) and 
phosphatase inhibitors (ThermoFisher Scientific) were 
added to the lysis buffer. Total cellular lysates (20μg for 
each sample) were loaded and separated on 10% SDS-
polyacrylamide gel and then transferred on a nitrocellulose 
membrane. To visualize loading and transfer, Ponceau 
staining has been performed. Membranes were then 
pre-blocked in a blocking solution of 0.1% tris-buffered 
saline Tween 20 (TBS-T) containing 5% Bovine Serum 
Albumin (BSA) and then incubated with the following 
primary antybodies: mouse monoclonal anti-SOCS6 
antibody (Abcam, Cambridge, UK, catalog #ab56516; 
1:500 dilution at 4°C overnight), mouse monoclonal anti-
PTEN antibody (Santa Cruz Biotechnology, Inc, Dallas, 
Texas, USA; catalog #sc-7974; 1:500 dilution for 1h and 
45 minutes at room temperature (RT)), rabbit monoclonal 
anti-STAT3 antibody (Cell Signaling Technology, Inc., 
catalog #4904; 1:1000 dilution at 4°C overnight), rabbit 
monoclonal anti-phospho-STAT3 antibody (phospho-
Ser727, Cell Signaling Technology, Inc., catalog #9134; 
1:250 dilution at 4°C overnight) and with rabbit polyclonal 
anti-β-actin primary antibody (Thermo Fisher Scientific 
Inc, catalog #PA1-16889; 1:2000 dilution for 1 hour at 
RT). The blots were washed for three times with TBS-T 
and then incubated with 1:5000 dilution of horseradish 
peroxidase (HRP) conjugated goat anti-mouse (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA catalog #sc-2005) 
and/or 1:1000 dilution of HRP-conjugated goat anti rabbit 
secondary antibody (Thermo Fisher Scientific Inc., catalog 
#32460) for 1h at RT. After three successive washes with 
TBS-T, BM chemiluminescence Blotting Substrate (POD) 
(Roche) was used for protein detection.
Statistical analysis
All the statistics used for data analysis in 
overexpression/silencing experiments and 3’UTR 
luciferase reporter assays were based on 2-tailed Student 
t-tests for average comparisons in paired samples. 
Data were then analyzed by means of Microsoft Excel 
(Microsoft Office, 2008 release) and have been reported 
as mean ± standard error of the mean (S.E.M). A p-value 
less than 0.05 was considered significant.
Correlation between miR-494-3p and SOCS6 
expression was displayed by means of Spearman's 
correlation.
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